HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


CYTX: Cytori Therapeutics De - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

CYTORI THERAPEUTICS DE (NASD)
CYTX 6.86 0.02 (0.29%) Vol.  33,664 09:43 ET

Day Low - High 6.79 - 6.90
52wk Low - High 1.42 - 9.50
Avg Volume 1,349,164
Industry MED-BIOMED/GENE
Market Cap 265.08 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -.52
EPS Last Year -0.62
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 01/12/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 12/14/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
CYTORI THERAPEUTICS DE CYTX PREMIUM
GILEAD SCIENCES GILD PREMIUM
ABRAXIS BIOSCI ABII PREMIUM
CURIS INC CRIS PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.50
ABR (Last Week) 2.50
# of Recs in ABR 4
Average Target Price 7.50
Industry Rank by ABR 68 out of 217
Rank in Industry 123 out of 162
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate CYTX?
Buy
Sell
Find out what the Zacks Community
thinks of CYTX at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR CYTX
Zacks Equity Research: Report for CYTX
Dec 14, 2009
Zacks Blog: Zacks Bull and Bear of the Day Highlights: Cytori Therapeutics, Red Robin Gourmet Burgers Inc., Ford, Eaton and TRW Automotive
Oct 19, 2009
Bull of the Day: Cytori Therapeutics (CYTX)
Oct 19, 2009
Zacks Blog: Zacks Analyst Blog Highlights: Cytori Therapeutics, Luminex Corp., Bank of NY Mellon, First Advantage Corporation and First American Corporation
Jun 30, 2009
Zacks Blog: Cytori's IP and Cash Position Solid
Jun 29, 2009
Zacks Blog: Cytori’s Celution Starting to Ramp
May 11, 2009
Zacks Blog: Zacks Bull & Bear of the Day Highlights: Cytori Therapeutics, Freddie Mac, Citigroup, Bank of America and Comerica
Mar 10, 2009
Bull of the Day: Cytori Therapeutics (CYTX)
Mar 10, 2009
More Zacks Commentary
NEWS
SmarTrend Detects Continued Selling Pressure in Shares of Cytori Therapeutics (CYTX)
Feb 03, 2010
Cosmetic Surgery Seishin in Japan to Leverage Cytori's StemSourceCell Bank
Jan 30, 2010
Cytori Therapeutics (CYTX) NewsBite - One Of Today's Top Losers
Jan 29, 2010
BiomedReports: News and FDA Updates for Cytori (NASDAQ:CYTX), Elan (NYSE:ELN), Enzon (Nasdaq:ENZN)
Jan 29, 2010
Cytori Earns Patent for Cell-Enriched Fat Grafting
Jan 29, 2010
BiomedReports: News and FDA Updates for Cytori (NASDAQ:CYTX), Elan (NYSE:ELN), Enzon (Nasdaq:ENZN)
Jan 28, 2010
Cytori's StemSource(R) Cell Bank to Be Installed at Leading Cosmetic & Reconstructive Surgery Network in Japan
Jan 27, 2010
Cytori Therapeutics: Cell-Enriched Fat Grafts Improve Long Term Graft Retention in Preclinical Study
Jan 27, 2010
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate -0.16 -0.14 -0.52 -0.51
Number of Estimates 4 2 4 4
Low Estimates -0.18 -0.14 -0.58 -0.74
High Estimate -0.15 -0.13 -0.39 -0.38
Year Ago EPS -0.22 -0.20 -1.12 -0.52
EPS Growth 27.27% 32.50% 53.79% 0.48%

More Estimates

COMPANY DESCRIPTION
Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Full Company Report
FINANCIALS
EPS TTM -.62
Sales 4.53
Net Income -20.26
Price/Earnings N/A
Price/Book N/A
Price/Cash Flow N/A
Price/Sales 50.71


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research